Over the past two decades the Human Papillomavirus (HPV) field has expanded to include a full spectrum of researchers and practitioners from previously distant disciplines. This expansion has led to the development of a truly transdisciplinary group of scientists focused on advancing our understanding of HPV and implementing best practices to eliminate HPV related diseases. Currently the spectrum of PV research ranges from basic viral pathogenesis to global health policy, such as international public health programs, health systems organization vaccine financing and procurement, through to HPV epidemiology and intervention trials in HPV vaccination, screening and treatment. The field also has significant clinical activity in pathology, gynecology, head and neck, gastroenterology (anal) and genitourinary (penile) oncology, as well as in HPV diagnostics and cancer and pre-cancer treatments. Scientists in the field have elucidated many of the mechanisms by which papillomaviruses infect cells, proceed through their life cycle and cause cellular transformation, but much remains to be done such as understanding the basis of persistent HPV infections. The roots of the field remain however, in the areas of basic molecular biology, PVs taxonomy and phylogenetic evolution of PVs, as well as in the topics of host and viral immunology. Collectively this research is leading to the development of novel immunotherapies and anti-viral treatments, an area that is rapidly advancing. More recently, the disciplines of communication, dissemination, and decision-making sciences have assumed larger prominence as the community begins the daunting task of bringing new and effective technologies to populations worldwide. To ensure implementation of best practices derived from our collective research, communication and educational expertise has been recognized as essential.

The HPV field is organizing itself into an established discipline. We have had a tradition of regular international meetings for over 25 years, typically every one to two years and a scientific society for a decade which has now crystallized into a permanent structure with a formal constitution. Starting in 2015, we will have a Journal devoted to showcasing cutting-edge research in all areas related to PV and the challenging emerging research on polyomaviruses.

*Papillomavirus Research* (acronym PVR) has been established with the goal of fostering cross-fertilization of disciplines and facilitating multidisciplinary research of the highest quality. Ultimately, through this platform PVR seeks to support continued investigation into basic virology and pathogenesis, as well as international action in cancer prevention and treatment as a natural follow up to decades of fertile PV research.

This knowledge has enabled the papillomavirus community to push the frontiers of cancer prevention to present the world with highly effective HPV vaccines and HPV testing systems validated and amenable to the needs of screening programs. These two achievements dramatically advance our opportunities to control not only cervical cancer but also a number of other HPV induced cancers affecting men and women worldwide. Only anti-smoking programs rival such a broad reach of global cancer prevention across multiple cancer types. It will also be an ambition of PVR and the International Papillomavirus Society (IPVS) to advance the international agenda to include action plans in HPV related cancer control and to continue the story of success written by so many colleagues worldwide to improve the longevity and quality of life of our populations.
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